Short™ AE-IGF-1, a bioengineered variant of human insulin-like growth factor-1 (IGF-1) designed specifically for cell culture. It explores its properties, applications, and advantages, making it an asset for researchers and biomanufacturers.

Key Features of Short™ AE-IGF-1

• Enhanced potency: This engineered variant boasts 100-fold greater potency compared to standard IGF-1, significantly boosting recombinant protein production in cell cultures.
• Reduced apoptosis: Short™ AE-IGF-1 effectively minimizes cell death (apoptosis) within cultures, promoting cell viability and growth.
• Animal-free production: Produced following GMP-like guidelines, Short™ AE-IGF-1 utilizes entirely animal-free components, catering to ethical and regulatory considerations.
• High purity: Stringent quality control ensures a highly purified product (=95% by RP-HPLC and =97% by SDS-PAGE analysis), minimizing potential interference in cell cultures.
• Low endotoxin content: With endotoxin levels below 0.1 EU/µg, Short™ AE-IGF-1 is ideal for sensitive mammalian cell cultures.
• Stable liquid format: Provided as a sterile-filtered (0.2 µm) liquid formulation in acetic acid (pH 2-4), Short™ AE-IGF-1 eliminates the need for reconstitution and ensures stability during transportation and storage at room temperature.
• Long shelf life: The product boasts a remarkable shelf life of 4 years under recommended storage conditions.

Applications

Short™ AE-IGF-1 caters to various cell culture applications, including:

• Research: Ideal for basic research involving cell proliferation, differentiation, and protein production.
• Large-scale biomanufacturing: Suited for large-scale production of recombinant proteins in bioreactors.
• Specific cell lines: Supports a wide range of commercially available cell lines like CHO, PER.C6, and HEK 293.
• Stem cell cultures: Enhances the growth and viability of embryonic, mesenchymal, and hematopoietic stem cells.

Dosage and Usage

The optimal dosage of Short™ AE-IGF-1 can vary depending on the specific cell line and application. The product datasheet suggests a starting range of 25-200 µg/L for fed-batch systems and 25-100 µg/L for perfusion systems. However, experimentation is recommended to determine the ideal concentration for each unique cell culture.

·  Convenient and Stable: Short™ AE-IGF-1 comes ready-to-use in a liquid format, eliminating the need for complex powder handling and minimizing variability in your experiments. Plus, it boasts a long shelf life and stability at room temperature for easy storage and handling.

·  Improved Efficiency: This innovative product enhances protein re-folding within your cultures, leading to higher concentrations of your target protein throughout the process. It also reduces interference from IGF-1 binding proteins, ultimately resulting in greater protein yield and recovery.

·  Cost-Effective Solution: Short™ AE-IGF-1 simplifies upstream manufacturing processes, significantly reducing production costs.

Short™ AE-IGF-1 presents a potent and user-friendly solution for researchers and biomanufacturers working with cell cultures. Its exceptional potency, animal-free origin, and convenient liquid format make it a valuable tool for enhancing cell growth, viability, and protein production.

• Short™ AE-IGF-1 is strictly for in-vitro applications and not intended for diagnostic or therapeutic purposes.
• CellRx, the manufacturer, provides technical support and expertise to optimize cell culture conditions for users.

Short™ AE-IGF-1 is a groundbreaking tool for cell culture applications, offering unparalleled potency, enhanced cell viability, and cost-effective scalability. Its animal-free, high-purity formulation and stable liquid format make it a reliable choice for both research and large-scale biomanufacturing. By simplifying processes and boosting protein yields, Short™ AE-IGF-1 addresses key challenges in cell culture workflows while aligning with ethical and regulatory standards. This innovative solution is poised to empower researchers and biomanufacturers in achieving superior results in cell-based applications.